Compare Incyte Corporation (INCY) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Incyte Corporation trades at $118.03 (market cap $23.11B), while First Trust NASDAQ 100 Technology Index Fund trades at $309.9. The key difference: Incyte Corporation is trading nearer its 52-week high, First Trust NASDAQ 100 Technology Index Fund nearer its low. Which is the better fit depends on your goals.
| INCY | QTEC | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $118.52 | $335.74 |
52-Week Low | $67.38 | $207.03 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
QTEC trades at $301.50, up 0.53% today, with a bearish technical signal overall. Key support lies at $298 and resistance at $302. The ETF provides equal-weighted exposure to top technology firms, tracking the Nasdaq-100 Technology Sector Index. Recent news highlights its broad tech sector focus and questions on AI and chip stock valuations.
Outlook remains tied to technology sector performance, with risks from market volatility and sector-specific headwinds. Investment opportunity lies in targeted tech exposure, but caution is warranted given overheated valuations in segments like AI.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
